Estela Noguera-Ortega, MSc, PhD
Research Associate of Medicine (Pulmonary, Allergy and Critical Care)
Department: Medicine
Contact information
3450 Hamilton Walk
Philadelphia, PA 19104
Philadelphia, PA 19104
Lab: 215-573-9848
Education:
BSc (Biotechnology)
Universitat Autonoma de Barcelona, 2009.
MSc (Applied Microbiology)
Universitat Autonoma de Barcelona, 2010.
PhD (Microbiology)
Universitat Autonoma de Barcelona, 2015.
Permanent linkBSc (Biotechnology)
Universitat Autonoma de Barcelona, 2009.
MSc (Applied Microbiology)
Universitat Autonoma de Barcelona, 2010.
PhD (Microbiology)
Universitat Autonoma de Barcelona, 2015.
Description of Research Expertise
My research currently focuses on adoptive T cell transfer, specifically the development of chimeric antigen receptor CAR T cells for use in solid tumors. The major areas of my interest have been augmentation of CAR T cells anti-tumor immune effects by optimizing CAR design, targeting the tumor microenvironment, improving T cell trafficking, and preventing T cell exhaustion.Selected Publications
Sharma G, Ojha R, Noguera-Ortega E, Rebecca VW, Attanasio J, Liu S, Piao S, Lee JJ, Nicastri MC, Harper SL, Ronghe A, Jain V, Winkler JD, Speicher DW, Mastio J, Gimotty PA, Xu X, Wherry EJ, Gabrilovich DI, Amaravadi RK.: PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma. JCI Insight 5: e133225, Sep 2020.Noguera-Ortega E, Guallar-Garrido S, Julián E.: Mycobacteria-Based Vaccines as Immunotherapy for Non-urological Cancers. Cancers (Basel) 12(7): 1802, Jul 2020.
Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, Powell DJ Jr, Guedan S.: CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. Front Immunol 11: 1109, Jun 2020.
Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude CI, Murugan S, Fennelly C, Noguera-Ortega E, Chu CT, Liu S, Xu X, Krepler C, Xiao M, Xu W, Wei Z, Frederick DT, Boland G, Mitchell TC, Karakousis GC, Schuchter LM, Flaherty KT, Zhang G, Herlyn M, Koumenis C, Amaravadi RK.: ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Cancer Discov 9(3): 396-415, Mar 2019.
Rebecca VW, Nicastri MC, Fennelly C, Chude CI, Barber-Rotenberg JS, Ronghe A, McAfee Q, McLaughlin NP, Zhang G, Goldman AR, Ojha R, Piao S, Noguera-Ortega E, Martorella A, Alicea GM, Lee JJ, Schuchter LM, Xu X, Herlyn M, Marmorstein R, Gimotty PA, Speicher DW, Winkler JD, Amaravadi RK.: PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer. Cancer Discov 9(2): 220-229, Feb 2019.
E Julián, E Noguera-Ortega: Bacteria-Derived Alternatives to Live Mycobacterium bovis Bacillus Calmette–Guerin for Nonmuscle Invasive Bladder Cancer Treatment. Microbial Infections and Cancer Therapy. Ananda M. Chakrabarty, Arsénio M. Fialho (eds.). Pan Stanford Publishing Pte. Ltd. Chapt. 4: 123-188, Feb 2019.
Noguera-Ortega E, Rabanal RM, Gómez-Mora E, Cabrera C, Luquin M, Julián E.: Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice. Sci Rep 8(1): 15102, Oct 2018.
Noguera-Ortega E, Amaravadi RK.: Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role? Cancer Discov 8(3): 266-268, Mar 2018.
E Noguera-Ortega, E Julián: Mycobacteria-Derived Agents for the Treatment of Urological and Renal Cancers. Mycobacterium-Research and Development. Wellman Ribón (eds.). IntechOpen, Dec 2017.
Brambilla C, Llorens-Fons M, Julián E, Noguera-Ortega E, Tomàs-Martínez C, Pérez-Trujillo M, Byrd TF, Alcaide F, Luquin M.: Mycobacteria Clumping Increase Their Capacity to Damage Macrophages. Front Microbiol 7: 1562, Oct 2016.